Baxter International Inc vs Core Scientific Inc — how do they compare? Baxter International Inc trades at $26.94 (market cap $14.27B), while Core Scientific Inc trades at $20.93 (market cap $6.35B). The key difference: Baxter International Inc is far larger — about 2.2× Core Scientific Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| BAX | CORZ | |
|---|---|---|
Market Cap | $14.27B | $6.35B |
Sector | Health | Technology |
52-Week High | $28.35 | $29.16 |
52-Week Low | $15.80 | $13.55 |
Enterprise Value | $21.79B | $8.88B |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
Core Scientific (CORZ) trades at $20.87, up 7.36% today, amid strong analyst support with 19 buy ratings and a $35.88 consensus price target. The stock shows bearish technical signals with resistance at $21, while fundamentals reveal significant losses (-$288.62M net income in 2025) despite revenue growth to $319M. Recent AMD partnership for 2.5GW data center capacity signals strategic pivot to AI infrastructure.
Outlook balances high growth potential from AI contracts against substantial cash burn and negative margins. Key risks include execution of expansion plans and profitability timeline, but institutional interest and analyst optimism suggest upside if operational targets are met.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →